• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Monday, September 8, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Confluence Pharmaceuticals receives $200K investment from IU fund

Bioengineer by Bioengineer
April 11, 2019
in Chemistry
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Confluence Pharmaceuticals develops treatments for social and communication impairments related to autism spectrum disorder, fragile X syndrome

IMAGE

Credit: Teri Willey

BLOOMINGTON, Ind. — The Indiana University Philanthropic Venture Fund, which invests in IU-related ventures, has invested $200,000 in Confluence Pharmaceuticals LLC.

Confluence Pharmaceuticals is a Carmel, Indiana-based company that develops novel, clinically discovered, therapeutic treatments for core social and communication impairments related to fragile X syndrome and autism spectrum disorder.

Confluence Pharmaceuticals CEO Steve Johns said the company is targeting its lead asset, a product for the treatment of fragile X syndrome to improve important functionality including communication, social interaction and self-care.

“Today, no medication exists to treat these core impairments,” Johns said. “Early pilot studies have demonstrated the potential of our product to improve focus, communication, social withdrawal and attention deficit hyperactivity disorder.”

Confluence Pharmaceuticals will use the investment to accelerate clinical development and regulatory activities.

What they’re saying

Confluence Pharmaceuticals licenses intellectual property developed at Indiana University through the IU Innovation and Commercialization Office.

“We are delighted to have Indiana University broaden its relationship with us and become an investor as we enter the next stage of our development,” Johns said. “We look forward to continuing our collaborative relationship and utilizing the supportive resources IU brings to the development of this much-needed therapy.”

The IU Philanthropic Venture Fund was launched in February 2018. Teri Willey is the fund manager and executive director of the IU Research and Technology Corp.

“We, too, are delighted to be supporting the team at Confluence in their efforts to bring this critical therapy to patients, and to have Confluence as our 10th investment since launching the fund a few months ago,” Willey said.

About Indiana University Research and Technology Corp.

IURTC catalyzes entrepreneurial activities at Indiana University and provides support for IU innovation-based startup companies. It advises and connects IU startups to capital and commercialization partners, industry mentors, and leadership talent. It also develops appropriate programming and startup space to accelerate company growth.

About Indiana University Philanthropic Venture Fund

The IU Philanthropic Venture Fund is an Indiana University-affiliated venture fund launched in 2018 through the vision and generosity of IU alumni and friends supporting IU discoveries best developed through a new venture. The fund is managed by IURTC staff who work with the IU Innovation and Commercialization Office, alumni, faculty, and staff, as well as the venture and economic development communities, to identify and develop IU-related opportunities for investment.

###

Media Contact
Steve Martin
[email protected]

Original Source

https://news.iu.edu/stories/2019/04/iu/11-confluence-pharmaceuticals-autism-fragile-x-investment-philanthropic-venture-fund.html?&ntm_campaign=iu_news&ntm_medium=web&ntm_source=news.iu.edu/topic/business-and-innovation/index.html&ntm_term=feature&ntm

Tags: Grants/FundingMedicine/HealthPharmaceutical Sciences
Share12Tweet8Share2ShareShareShare2

Related Posts

Scientists Convert Plastic Waste into High-Performance CO2 Capture Materials

Scientists Convert Plastic Waste into High-Performance CO2 Capture Materials

September 5, 2025
Decoding Orderly and Disorderly Behavior in 2D Nanomaterials: Paving the Way for AI-Driven Custom Designs

Decoding Orderly and Disorderly Behavior in 2D Nanomaterials: Paving the Way for AI-Driven Custom Designs

September 5, 2025

Physicists Develop Visible Time Crystal for the First Time

September 5, 2025

Adaptive Visible-Infrared Camouflage Enables Wide-Spectrum Radiation Control for Extreme Temperature Environments

September 5, 2025
Please login to join discussion

POPULAR NEWS

  • blank

    Breakthrough in Computer Hardware Advances Solves Complex Optimization Challenges

    150 shares
    Share 60 Tweet 38
  • New Drug Formulation Transforms Intravenous Treatments into Rapid Injections

    116 shares
    Share 46 Tweet 29
  • First Confirmed Human Mpox Clade Ib Case China

    56 shares
    Share 22 Tweet 14
  • A Laser-Free Alternative to LASIK: Exploring New Vision Correction Methods

    47 shares
    Share 19 Tweet 12

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Confronting Weight Stigma: Educating Future Medical Professionals

Modified Coxsackie B1 Vaccine Induces Strong Antibody Response

Novel Non-Hormonal Biomaterial Shows Promise in Mitigating Vaginal Changes Linked to Menopause

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.